Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Cirrhosis

Free Subscription Articles published in Hepatology Retrieve available abstracts of 282 articles: HTML format

Single Articles

July 2026
1. ZHANG Y, Lee HW, Lin H, Tsochatzis E, et al
   Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease.
   Hepatology. 2026;84:175-190.
   PubMed     Abstract available
   
   
   
2. DUAN X, Li S, Li Q, Wen W, et al
   HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner.
   Hepatology. 2026;84:216-232.
   PubMed     Abstract available
   
   
   
3. YOUNOSSI ZM, de Avila L, Petta S, Hagstrom H, et al
   Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.
   Hepatology. 2026;84:204-215.
   PubMed     Abstract available
   
   
   
4. YOUNOSSI ZM, de Avila L, Petta S, Hagstrom H, et al
   Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study.
   Hepatology. 2026;84:161-174.
   PubMed     Abstract available
   
   
   
5. SIMON-CODINA B, Cacho-Pujol J, Moles A, Melgar-Lesmes P, et al
   Reprogramming macrophages to treat liver diseases.
   Hepatology. 2026;84:251-272.
   PubMed     Abstract available
   
   
   June 2026
6. HUI VW, Tang JC, Wong VW, Liang LY, et al
   HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression.
   Hepatology. 2026 Jun 8. doi: 10.1097/HEP.0000000000001804.
   PubMed     Abstract available
   
   
   
7. OZMERT EH
   Spit happens: Microbial and metabolic clues to cirrhosis hospitalization.
   Hepatology. 2026;83:1345-1346.
   PubMed    
   
   
   May 2026
8. GU H, Arab JP
   Beyond clinical comorbidities: Social determinants of health shape cirrhosis risk.
   Hepatology. 2026;83:1027-1028.
   PubMed    
   
   
   
9. CHALASANI N, Vuppalanchi R, Noureddin M, Shiffman ML, et al
   Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.
   Hepatology. 2026 May 1. doi: 10.1097/HEP.0000000000001774.
   PubMed     Abstract available
   
   
   April 2026
10. PILAR BALLESTER M, Carbonell-Asins JA, Elshabrawi A, Rubin D, et al
    A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
    Hepatology. 2026 Apr 3. doi: 10.1097/HEP.0000000000001748.
    PubMed     Abstract available
    
    
    
11. SIDHU G
    When "trace" is not trivial: Mild ascites as the missing prognostic middle ground in cirrhosis.
    Hepatology. 2026;83:695-696.
    PubMed    
    
    
    
12. LOOMBA R, Daniel PCN, Amangurbanova M, Bettencourt R, et al
    Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy.
    Hepatology. 2026;83:907-914.
    PubMed     Abstract available
    
    
    March 2026
13. LIANG Z, Jin H, Gao W, Hu X, et al
    Prospective head-to-head comparison of routine non-invasive scores for predicting severe cirrhosis-related morbidity in the general population.
    Hepatology. 2026 Mar 23. doi: 10.1097/HEP.0000000000001749.
    PubMed     Abstract available
    
    
    
14. VAN KLEEF LA, Pustjens J, Schattenberg JM, Holleboom AG, et al
    Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.
    Hepatology. 2026;83:591-602.
    PubMed     Abstract available
    
    
    
15. SCHWIMMER JB, Thai NQN, Noon SL, Ugalde-Nicalo P, et al
    Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study.
    Hepatology. 2026;83:561-574.
    PubMed     Abstract available
    
    
    
16. HAGHNEJAD V, Burke L, El Ouahabi S, Parker R, et al
    Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review.
    Hepatology. 2026;83:530-551.
    PubMed     Abstract available
    
    
    February 2026
17. ZHANG P, Liu D, Wu L, Wu X, et al
    Neutrophil serine proteases NE and PR3 controlled by the miR-223/STAT3 axis potentiate MASH and liver fibrosis.
    Hepatology. 2026;83:317-332.
    PubMed     Abstract available
    
    
    January 2026
18. KHAN S
    PSC and HCC: Age and cirrhosis draw the line on risk.
    Hepatology. 2026;83:1.
    PubMed    
    
    
    
19. HAZARI Y, Habbouche L, Garcia Lopez VA, Urra H, et al
    Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.
    Hepatology. 2026;83:75-93.
    PubMed     Abstract available
    
    
    
20. PANAGIOTOPOULOS N, Wolfson T, Harris DT, Batakis D, et al
    Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:127-141.
    PubMed     Abstract available
    
    
    
21. HARRISON SA, Dubourg J, Knott M, Colca J, et al
    Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:169-177.
    PubMed     Abstract available
    
    
    December 2025
22. KORATALA A, Argaiz ER
    Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
    PubMed    
    
    
    
23. PREMKUMAR M, Kajal K
    Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
    PubMed    
    
    
    
24. JI J, Chen Z, He W, Chen Y, et al
    CXCR6 defines a distinct resident state in gammadelta T cells for protecting from liver cirrhosis.
    Hepatology. 2025 Dec 11. doi: 10.1097/HEP.0000000000001643.
    PubMed     Abstract available
    
    
    November 2025
25. BANSAL MB, Patton H, Morgan TR, Carr RM, et al
    Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
    Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001608.
    PubMed     Abstract available
    
    
    
26. DANPANICHKUL P, Duangsonk K, Chen VL, Saokhieo P, et al
    Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.
    Hepatology. 2025;82:1274-1286.
    PubMed     Abstract available
    
    
    
27. UNALP-ARIDA A, Ruhl CE
    Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
    Hepatology. 2025;82:1256-1273.
    PubMed     Abstract available
    
    
    
28. NOUREDDIN M
    MASH clinical trials and drugs pipeline: An impending tsunami.
    Hepatology. 2025;82:1325-1340.
    PubMed     Abstract available
    
    
    October 2025
29. WALIA N, Hui S, Braude M
    Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
    PubMed    
    
    
    
30. JOHN BV, Bastaich D, Singal AG, Dahman B, et al
    Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
    PubMed    
    
    
    
31. PATIDAR KR, Sharma P
    Time to focus on POCUS For AKI management in cirrhosis.
    Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
    PubMed    
    
    
    
32. ABAD-JORDA L, Andres-Rozas M, Martinez-Alcocer A, Aspas J, et al
    Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
    Hepatology. 2025 Oct 10. doi: 10.1097/HEP.0000000000001567.
    PubMed     Abstract available
    
    
    
33. HUANG X, Lisman T
    Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder.
    Hepatology. 2025 Oct 8. doi: 10.1097/HEP.0000000000001565.
    PubMed    
    
    
    
34. ANTON A, Shalaby S, Botero ML, Blasi A, et al
    Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
    Hepatology. 2025 Oct 6. doi: 10.1097/HEP.0000000000001547.
    PubMed     Abstract available
    
    
    September 2025
35. PREMKUMAR M, Kajal K, Roy A, Izzy M, et al
    'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001524.
    PubMed     Abstract available
    
    
    
36. HAGHNEJAD V, Burke L, El Ouahabi S, Parker R, et al
    Reply: a prognostic model in patients with alcohol-related cirrhosis does exist.
    Hepatology. 2025 Sep 18. doi: 10.1097/HEP.0000000000001537.
    PubMed    
    
    
    
37. DELTENRE P, Marot A, Henrion J
    A prognostic model in patients with alcohol-related cirrhosis does exist.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001532.
    PubMed    
    
    
    
38. LI W, Chi Y, Xiao X, Li J, et al
    Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
    Hepatology. 2025;82:669-682.
    PubMed     Abstract available
    
    
    
39. SUN Y, Chen S, Xu X, Piao H, et al
    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
    PubMed     Abstract available
    
    
    August 2025
40. INDRE MG, Leucuta DC, Lupsor-Platon M, Turco L, et al
    Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.
    Hepatology. 2025;82:454-469.
    PubMed     Abstract available
    
    
    July 2025
41. TELLEZ L, Toledano M, Alvarez M, Garrido-Lestache E, et al
    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001472.
    PubMed     Abstract available
    
    
    
42. SEIF EL DAHAN K, Daher D, Rich NE, Nayak AJ, et al
    Causes of mortality among patients with early-stage hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001471.
    PubMed     Abstract available
    
    
    
43. MARTINS A, Khakoo NS, Reddy A, Reynolds JM, et al
    Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001465.
    PubMed     Abstract available
    
    
    
44. BAJAJ JS, Reddy KR, Tandon P, Lai JC, et al
    Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort.
    Hepatology. 2025 Jul 9. doi: 10.1097/HEP.0000000000001462.
    PubMed     Abstract available
    
    
    
45. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    PubMed     Abstract available
    
    
    
46. CHONG LUGON N, Rabiee A, Mezzacappa C, Kaplan DE, et al
    Prognostic significance of mild ascites in patients with cirrhosis.
    Hepatology. 2025 Jul 3. doi: 10.1097/HEP.0000000000001452.
    PubMed     Abstract available
    
    
    June 2025
47. CHUNG BK, Jordens MS, Ogaard J, Reims HM, et al
    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001432.
    PubMed     Abstract available
    
    
    
48. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    PubMed     Abstract available
    
    
    
49. SHAW J, Acharya C, Fagan A, Olofson A, et al
    Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001424.
    PubMed     Abstract available
    
    
    
50. PEDDU DK, Tedesco N, Rutledge SM, Wijarnpreecha K, et al
    Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001420.
    PubMed     Abstract available
    
    
    
51. HARRIS K
    LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
    Hepatology. 2025;81:1625-1626.
    PubMed    
    
    
    
52. TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
    Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025;81:1792-1804.
    PubMed     Abstract available
    
    
    May 2025
53. XIE L, Chen H, Zhang L, Yang YY, et al
    Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
    PubMed     Abstract available
    
    
    
54. WANG C, Dong D, Zhao N, Zhao S, et al
    Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
    PubMed     Abstract available
    
    
    
55. CHAGANTI J, Zeng G, Patil A, Lockart I, et al
    Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
    Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
    PubMed     Abstract available
    
    
    April 2025
56. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    PubMed     Abstract available
    
    
    
57. ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
    Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
    PubMed    
    
    
    
58. TANTAI X, Li L, Dai S
    Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
    PubMed    
    
    
    
59. TANTAI X, Li L, Dai S
    Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
    PubMed    
    
    
    
60. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
    Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
    PubMed    
    
    
    
61. NOBEL YR, Boike JR, Mazumder NR, Thornburg B, et al
    Predictors of long-term clinical outcomes after TIPS: An ALTA group study.
    Hepatology. 2025;81:1244-1255.
    PubMed     Abstract available
    
    
    
62. OJHA U, Kim S, Rhee CY, You J, et al
    Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
    Hepatology. 2025;81:1228-1243.
    PubMed     Abstract available
    
    
    
63. LEFERE S, Mosca A, Hudert C, Dupont E, et al
    Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD.
    Hepatology. 2025;81:1276-1287.
    PubMed     Abstract available
    
    
    
64. HLADY RA, Zhao X, El Khoury LY, Wagner RT, et al
    Epigenetic heterogeneity hotspots in human liver disease progression.
    Hepatology. 2025;81:1197-1210.
    PubMed     Abstract available
    
    
    
65. MOL B, Werner E, Culver EL, van der Meer AJ, et al
    Epidemiological and economical burden of cholestatic liver disease.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
    PubMed     Abstract available
    
    
    March 2025
66. SU R, Tao X, Yan L, Liu Y, et al
    Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
    PubMed     Abstract available
    
    
    
67. ZHAO Q, Liu H, Yang Z, Han X, et al
    Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells.
    Hepatology. 2025 Mar 13. doi: 10.1097/HEP.0000000000001302.
    PubMed     Abstract available
    
    
    February 2025
68. CARDOSO FS
    Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001288.
    PubMed    
    
    
    
69. WONG GL, Chan HL
    Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
    Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
    PubMed    
    
    
    
70. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    PubMed     Abstract available
    
    
    
71. SOUZA M, Al-Sharif L, Antunes VLJ, Huang DQ, et al
    Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
    Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
    PubMed     Abstract available
    
    
    
72. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2025;81:609-624.
    PubMed     Abstract available
    
    
    
73. BURTIS AEC, DeNicola DMC, Ferguson ME, Santos RG, et al
    Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice.
    Hepatology. 2025;81:591-608.
    PubMed     Abstract available
    
    
    
74. FEIO-AZEVEDO R, Boesch M, Radenkovic S, van Melkebeke L, et al
    Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
    Hepatology. 2025;81:509-522.
    PubMed     Abstract available
    
    
    
75. WONG YJ, Chen VL, Abdulhamid A, Tosetti G, et al
    Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
    Hepatology. 2025;81:523-531.
    PubMed     Abstract available
    
    
    
76. DUARTE-ROJO A, Taouli B, Leung DH, Levine D, et al
    Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:725-748.
    PubMed     Abstract available
    
    
    January 2025
77. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
    Prevalence and predictors of cirrhosis and portal hypertension in the united states.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
    PubMed     Abstract available
    
    
    
78. DESPLATS V, Haudebourg L, Verger N, Assaraf J, et al
    Acute encephalopathy without hyperammonemia has a different presentation than overt hepatic encephalopathy and displays similarly severe prognosis.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001252.
    PubMed     Abstract available
    
    
    
79. OBRADOVIC F, Vitello DJ, Hasjim BJ, Obayemi J, et al
    Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.
    Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
    PubMed     Abstract available
    
    
    
80. ROCCARINA D, Saltini D, Adotti V, Rosi M, et al
    End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001224.
    PubMed     Abstract available
    
    
    
81. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    PubMed     Abstract available
    
    
    
82. KABELITZ MA, Hartl L, Schaub G, Tiede A, et al
    Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001219.
    PubMed     Abstract available
    
    
    
83. WILECHANSKY RM
    Putting mean arterial pressure on the map as an AKI biomarker in cirrhosis.
    Hepatology. 2025;81:3-4.
    PubMed    
    
    
    
84. PATEL K, Asrani SK, Fiel MI, Levine D, et al
    Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:358-379.
    PubMed     Abstract available
    
    
    December 2024
85. TAO J, Wu Z, Liang Y, Wang J, et al
    Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
    PubMed     Abstract available
    
    
    
86. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    PubMed     Abstract available
    
    
    November 2024
87. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    PubMed     Abstract available
    
    
    
88. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
    Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
    Hepatology. 2024 Nov 8. doi: 10.1097/HEP.0000000000001146.
    PubMed     Abstract available
    
    
    
89. ALVARADO-TAPIAS E, Brujats A, Puente A, Ardevol A, et al
    Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized-trial.
    Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148.
    PubMed     Abstract available
    
    
    
90. NARAYANAN P
    PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.
    Hepatology. 2024;80:991-992.
    PubMed    
    
    
    
91. CHARU V, Liang JW, Mannalithara A, Kwong A, et al
    Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD.
    Hepatology. 2024;80:1184-1195.
    PubMed     Abstract available
    
    
    
92. CHALASANI N, Vilar-Gomez E, Loomba R, Yates KP, et al
    PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2024;80:1212-1226.
    PubMed     Abstract available
    
    
    October 2024
93. KIM JW, Tung HC, Ke M, Xu P, et al
    The de-sulfinylation enzyme sulfiredoxin-1 attenuates hepatic stellate cell activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.
    Hepatology. 2024 Oct 24. doi: 10.1097/HEP.0000000000001133.
    PubMed     Abstract available
    
    
    
94. KEZER CA, Berzigotti A, Fortune BE, Simonetto DA, et al
    Drug treatments to prevent first decompensation in cirrhosis.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001117.
    PubMed     Abstract available
    
    
    
95. FAR A, Bastani A, Lee A, Gologorskaya O, et al
    Evaluating the positive predictive value of code-based identification of cirrhosis and its complications utilizing GPT-4.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001115.
    PubMed     Abstract available
    
    
    
96. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    PubMed     Abstract available
    
    
    September 2024
97. BLOOM PP, Fisher CJ, Tedesco N, Kamdar N, et al
    HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
    Hepatology. 2024 Sep 12. doi: 10.1097/HEP.0000000000001086.
    PubMed     Abstract available
    
    
    
98. YOUNOSSI ZM, Stepanova M, Racila A, Henry L, et al
    Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis.
    Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
    PubMed     Abstract available
    
    
    
99. TERBAH R, Testro AG, Hoermann R, Majumdar A, et al
    Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study.
    Hepatology. 2024;80:605-620.
    PubMed     Abstract available
    
    
    August 2024
100. LUCAS MR, Pilling LC, Atkins JL, Melzer D, et al
     Incidence of liver complications with hemochromatosis associated HFE p.C282Y homozygosity: The role of central adiposity.
     Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001056.
     PubMed     Abstract available
     
     
     
101. SHANG Y, Akbari C, Dodd M, Zhang X, et al
     Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045.
     PubMed     Abstract available
     
     
     
102. NAULT JC, Iavarone M
     Management of patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab: Take care of cirrhosis!
     Hepatology. 2024 Aug 5. doi: 10.1097/HEP.0000000000001047.
     PubMed    
     
     
     July 2024
103. WANG M, Chiou SH, Ganger D, Ruck J, et al
     Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study.
     Hepatology. 2024 Jul 24. doi: 10.1097/HEP.0000000000001030.
     PubMed     Abstract available
     
     
     
104. 
     Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
     Hepatology. 2024;80:E23.
     PubMed    
     
     
     
105. 
     Erratum: The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
     Hepatology. 2024;80:E22.
     PubMed    
     
     
     
106. MA J, Liangpunsakul S
     Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
     Hepatology. 2024;80:14-17.
     PubMed    
     
     
     
107. DAVENPORT M
     Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
     Hepatology. 2024;80:18-19.
     PubMed    
     
     
     
108. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
     Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
     Hepatology. 2024;80:163-172.
     PubMed     Abstract available
     
     
     
109. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
     Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
     Hepatology. 2024;80:119-135.
     PubMed     Abstract available
     
     
     
110. PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
     Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
     Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
     PubMed     Abstract available
     
     
     June 2024
111. RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
     Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
     Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
     PubMed     Abstract available
     
     
     
112. KANG K, Wu Y
     Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
     PubMed    
     
     
     
113. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
     Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
     PubMed    
     
     
     
114. 
     Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
     PubMed    
     
     
     
115. HUANG L, Zou L
     Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
     PubMed    
     
     
     
116. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
     Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E155-E156.
     PubMed    
     
     
     
117. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
     Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E153-E154.
     PubMed    
     
     
     
118. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
     Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
     Hepatology. 2024;79:1401-1411.
     PubMed     Abstract available
     
     
     
119. WANG A, Blackford AL, Behling C, Wilson LA, et al
     Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:1381-1392.
     PubMed     Abstract available
     
     
     May 2024
120. GUO C, Liu Z, Zhang T
     Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
     PubMed    
     
     
     
121. MUSSO G, Pinach S, Mariano F, Saba F, et al
     Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
     PubMed     Abstract available
     
     
     
122. MOORE MP, Wang X, Kennelly JP, Shi H, et al
     Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
     Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
     PubMed     Abstract available
     
     
     
123. LIU H, Li H, Wang DX, Li T, et al
     Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:E144-E145.
     PubMed    
     
     
     
124. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
     Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     Hepatology. 2024;79:E146-E147.
     PubMed    
     
     
     
125. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
     Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:1107-1116.
     PubMed     Abstract available
     
     
     
126. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
     Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
     Hepatology. 2024;79:1098-1106.
     PubMed     Abstract available
     
     
     April 2024
127. KUMAR M, Venishetty S
     Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
     Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
     PubMed    
     
     
     
128. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
     Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
     PubMed    
     
     
     
129. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
     A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
     Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
     PubMed     Abstract available
     
     
     
130. GUO C, Liu Z, Fan H, Wang H, et al
     Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
     Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
     PubMed     Abstract available
     
     
     
131. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
     Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
     PubMed    
     
     
     
132. GARCIA-TSAO G, Kaplan DE
     Reply: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
     PubMed    
     
     
     
133. VOLK ML
     Innovations in Healthcare Delivery for Patients with Cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
     PubMed    
     
     
     
134. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
     Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
     Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
     PubMed     Abstract available
     
     
     
135. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
     Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
     Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
     PubMed     Abstract available
     
     
     March 2024
136. 
     Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
     Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
     PubMed    
     
     
     
137. CRUZ C, Prado CM, Gillis C, Martindale R, et al
     Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
     PubMed     Abstract available
     
     
     
138. FENG X, Feng B, Zhou J, Yang J, et al
     Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
     PubMed     Abstract available
     
     
     
139. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
     The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
     PubMed     Abstract available
     
     
     
140. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
     A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
     PubMed     Abstract available
     
     
     
141. JONES DE, Beuers U, Bonder A, Carbone M, et al
     Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
     PubMed     Abstract available
     
     
     
142. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
     Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
     PubMed     Abstract available
     
     
     
143. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
     Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
     Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
     PubMed     Abstract available
     
     
     
144. MUNOZ AE, Rodger EG
     Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
     PubMed    
     
     
     
145. SHARPTON S, Loomba R
     Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
     PubMed    
     
     
     
146. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
     Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
     PubMed     Abstract available
     
     
     
147. BU W, Sun X, Xue X, Geng S, et al
     Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
     PubMed     Abstract available
     
     
     
148. CHAPMAN B, Wong D, Sinclair M, Hey P, et al
     Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial.
     Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000840.
     PubMed     Abstract available
     
     
     
149. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
     Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
     Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
     PubMed     Abstract available
     
     
     
150. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
     Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
     PubMed     Abstract available
     
     
     
151. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
     Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
     PubMed     Abstract available
     
     
     
152. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
     Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
     PubMed     Abstract available
     
     
     
153. 
     Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
     Hepatology. 2024;79:E105.
     PubMed    
     
     
     
154. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
     Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
     Hepatology. 2024;79:624-635.
     PubMed     Abstract available
     
     
     
155. WANG F, Chen L, Kong D, Zhang X, et al
     Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
     Hepatology. 2024;79:606-623.
     PubMed     Abstract available
     
     
     
156. LEE BP, Dodge JL, Terrault NA
     National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
     Hepatology. 2024;79:666-673.
     PubMed     Abstract available
     
     
     February 2024
157. WONG YJ, Teng M, Sim A, Thet HM, et al
     Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
     PubMed     Abstract available
     
     
     
158. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
     Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
     PubMed     Abstract available
     
     
     
159. PENG Z, Wei G, Huang P, Matta H, et al
     ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
     PubMed     Abstract available
     
     
     
160. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
     A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
     Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
     PubMed     Abstract available
     
     
     
161. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
     Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
     PubMed    
     
     
     
162. AGRAWAL D, Ariga KK
     Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
     PubMed    
     
     
     
163. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
     From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
     PubMed     Abstract available
     
     
     
164. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
     Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
     Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
     PubMed     Abstract available
     
     
     
165. MENG Z, Zhou L, Hong S, Qiu X, et al
     Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
     Hepatology. 2024;79:409-424.
     PubMed     Abstract available
     
     
     
166. SINHA S, Hassan N, Schwartz RE
     Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
     Hepatology. 2024;79:482-501.
     PubMed     Abstract available
     
     
     January 2024
167. XIA Y, Wang Y, Xiong Q, He J, et al
     Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
     PubMed     Abstract available
     
     
     
168. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
     Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
     Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
     PubMed     Abstract available
     
     
     
169. ROWE IA
     Prediction of outcomes in patients with acute variceal bleeding.
     Hepatology. 2024;79:15-17.
     PubMed    
     
     
     
170. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
     Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
     Hepatology. 2024;79:183-197.
     PubMed     Abstract available
     
     
     
171. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
     Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
     Hepatology. 2024;79:39-48.
     PubMed     Abstract available
     
     
     December 2023
172. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
     Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
     PubMed     Abstract available
     
     
     
173. JENG WJ, Chien RN, Liaw YF
     Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
     PubMed    
     
     
     
174. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
     Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
     PubMed    
     
     
     
175. WIEGAND J, Franke A, Stein K, Trautwein C, et al
     Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
     PubMed    
     
     
     
176. CHEN J, Tu T, Cohen C, Wang S, et al
     Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
     PubMed    
     
     
     
177. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
     Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
     Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
     PubMed     Abstract available
     
     
     
178. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
     Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
     Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
     PubMed     Abstract available
     
     
     
179. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
     Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
     Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
     PubMed     Abstract available
     
     
     
180. 
     Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
     Hepatology. 2023;78:E108.
     PubMed    
     
     
     
181. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
     PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
     Hepatology. 2023;78:1788-1799.
     PubMed     Abstract available
     
     
     
182. ABERG F
     Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E101-E102.
     PubMed    
     
     
     
183. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E103-E104.
     PubMed    
     
     
     
184. MAIWALL R, Piano S, Singh V, Caraceni P, et al
     Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
     Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
     PubMed     Abstract available
     
     
     November 2023
185. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
     Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
     PubMed     Abstract available
     
     
     
186. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
     Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
     PubMed     Abstract available
     
     
     
187. HE S, Peng Y, Wei Q
     Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
     PubMed    
     
     
     
188. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
     Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
     PubMed    
     
     
     
189. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
     AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
     PubMed    
     
     
     
190. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
     Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
     PubMed     Abstract available
     
     
     
191. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
     Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
     Hepatology. 2023;78:E87-E88.
     PubMed    
     
     
     
192. TILG H, Adolph TE, Tacke F
     Therapeutic modulation of the liver immune microenvironment.
     Hepatology. 2023;78:1581-1601.
     PubMed     Abstract available
     
     
     
193. SONG Y, Wei J, Li R, Fu R, et al
     Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
     Hepatology. 2023;78:1433-1447.
     PubMed     Abstract available
     
     
     
194. BRAILLON A, Naudet F
     Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
     PubMed    
     
     
     
195. LEE CM, Yoon EL, Kim M, Kang BK, et al
     Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
     PubMed     Abstract available
     
     
     October 2023
196. JENG WJ, Chien RN, Liaw YF
     Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
     PubMed    
     
     
     
197. DENG R, Wang Z, Liu Y, Sun J, et al
     Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
     PubMed    
     
     
     
198. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
     Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
     PubMed    
     
     
     
199. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
     Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
     Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
     PubMed     Abstract available
     
     
     
200. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
     AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
     PubMed    
     
     
     
201. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
     Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
     PubMed     Abstract available
     
     
     
202. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
     Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
     PubMed    
     
     
     
203. LIAW YF, Jeng WJ, Chien RN
     Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
     PubMed    
     
     
     
204. MA S, Chew V
     Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
     PubMed    
     
     
     
205. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
     Non-invasive assessment of hepatic decompensation.
     Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
     PubMed     Abstract available
     
     
     
206. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
     Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
     Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
     PubMed     Abstract available
     
     
     
207. CHEN W, Sun Y, Chen S, Ge X, et al
     Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
     Hepatology. 2023;78:1118-1132.
     PubMed     Abstract available
     
     
     
208. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
     Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
     Hepatology. 2023;78:1200-1208.
     PubMed     Abstract available
     
     
     
209. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
     Intermittent fasting-the future treatment in NASH patients?
     Hepatology. 2023;78:1290-1305.
     PubMed     Abstract available
     
     
     
210. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
     Predicting liver-related events in NAFLD: A predictive model.
     Hepatology. 2023;78:1240-1251.
     PubMed     Abstract available
     
     
     
211. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
     Semaphorin 3C exacerbates liver fibrosis.
     Hepatology. 2023;78:1092-1105.
     PubMed     Abstract available
     
     
     September 2023
212. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
     The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
     Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
     PubMed     Abstract available
     
     
     
213. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
     A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
     PubMed     Abstract available
     
     
     
214. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
     Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
     PubMed     Abstract available
     
     
     
215. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
     Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
     PubMed     Abstract available
     
     
     
216. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
     Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
     PubMed     Abstract available
     
     
     August 2023
217. GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
     Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
     PubMed     Abstract available
     
     
     
218. JENG WJ, Chien RN, Chen YC, Lin CL, et al
     Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
     PubMed     Abstract available
     
     
     
219. CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
     Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
     PubMed     Abstract available
     
     
     
220. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
     Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
     Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
     PubMed     Abstract available
     
     
     
221. CHANG X, Lv C, Wang B, Wang J, et al
     The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
     Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000563.
     PubMed     Abstract available
     
     
     
222. JIANPING D, Xi C, Guangwen C, Fankun M, et al
     Dual elastography to discriminate adjacent stages of fibrosis and inflammation in chronic hepatitis B: A prospective multicenter study.
     Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000566.
     PubMed     Abstract available
     
     
     
223. LV Y, Bai W, Zhu X, Xue H, et al
     Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
     Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
     PubMed     Abstract available
     
     
     
224. TREBICKA J, Garcia-Tsao G
     Controversies regarding albumin therapy in cirrhosis.
     Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
     PubMed     Abstract available
     
     
     
225. BOWLUS CL, Levy C
     Optimizing treatment of primary biliary cholangitis: Is good, good enough?
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
     PubMed    
     
     
     
226. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
     Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
     PubMed     Abstract available
     
     
     July 2023
227. SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
     Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
     Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
     PubMed     Abstract available
     
     
     
228. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
     Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
     Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
     PubMed     Abstract available
     
     
     
229. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
     Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
     PubMed    
     
     
     
230. HU Y, Li Z, He W, Wang X, et al
     Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
     PubMed    
     
     
     
231. NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
     Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
     Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
     PubMed     Abstract available
     
     
     
232. CHEEMA MRS
     Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2023;78:E18.
     PubMed    
     
     
     
233. LEE J, Westphal M, Vali Y, Boursier J, et al
     Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
     Hepatology. 2023;78:258-271.
     PubMed     Abstract available
     
     
     
234. PENNISI G, Enea M, Falco V, Aithal GP, et al
     Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
     Hepatology. 2023;78:195-211.
     PubMed     Abstract available
     
     
     
235. ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
     Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
     Hepatology. 2023;78:284-294.
     PubMed     Abstract available
     
     
     
236. KONG M, Dong W, Kang A, Kuai Y, et al
     Regulatory role and translational potential of CCL11 in liver fibrosis.
     Hepatology. 2023;78:120-135.
     PubMed     Abstract available
     
     
     June 2023
237. TAPPER EB, Lai JC
     Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
     PubMed    
     
     
     May 2023
238. JESUDIAN AB, Fortune BE
     The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
     Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
     PubMed    
     
     
     
239. CARR RM, Li Y, Chau L, Friedman ES, et al
     An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
     Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
     PubMed     Abstract available
     
     
     
240. GILGENKRANTZ H, Paradis V, Lotersztajn S
     Cell metabolism-based therapy for liver fibrosis, repair and hepatocellular carcinoma.
     Hepatology. 2023 May 23. doi: 10.1097/HEP.0000000000000479.
     PubMed     Abstract available
     
     
     
241. LV Y, Han G
     Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
     PubMed    
     
     
     
242. YIN HJ, Wan YM
     Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
     PubMed    
     
     
     
243. KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
     Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
     PubMed     Abstract available
     
     
     
244. TONON M, Balcar L, Semmler G, Calvino V, et al
     Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
     Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
     PubMed     Abstract available
     
     
     
245. MALLET M, Silaghi CA, Sultanik P, Conti F, et al
     Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
     PubMed     Abstract available
     
     
     
246. SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
     Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
     Hepatology. 2023;77:1702-1711.
     PubMed     Abstract available
     
     
     
247. RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
     AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
     Hepatology. 2023;77:1797-1835.
     PubMed    
     
     
     
248. KNIGHT GM, Thornburg B, Salem R
     Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
     Hepatology. 2023;77:E93-E94.
     PubMed    
     
     
     
249. GU W, Queck A, Trebicka J, Praktiknjo M, et al
     Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
     Hepatology. 2023;77:E101.
     PubMed    
     
     
     
250. NG CH, Chan KE, Muthiah M, Tan C, et al
     Examining the interim proposal for name change to steatotic liver disease in the US population.
     Hepatology. 2023;77:1712-1721.
     PubMed     Abstract available
     
     
     
251. ZHANG S, Wan D, Zhu M, Wang G, et al
     CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
     Hepatology. 2023;77:1612-1629.
     PubMed     Abstract available
     
     
     
252. AHMED A, Arshad MW, Ibrahim H
     Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
     PubMed    
     
     
     
253. CULLARO G
     Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
     PubMed    
     
     
     April 2023
254. UFERE NN
     Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
     PubMed    
     
     
     
255. TAPPER EB, Ospina E, Salim N, Chen X, et al
     Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
     Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
     PubMed     Abstract available
     
     
     
256. RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
     Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
     Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
     PubMed     Abstract available
     
     
     
257. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
     Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
     Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
     PubMed     Abstract available
     
     
     
258. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
     CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
     Hepatology. 2023;77:1241-1252.
     PubMed     Abstract available
     
     
     
259. GUERRIERI F, Levrero M
     HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
     Hepatology. 2023;77:1088-1089.
     PubMed    
     
     
     
260. LIU Z, Tan M, Ding H
     Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
     Hepatology. 2023;77:E71.
     PubMed    
     
     
     
261. YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
     Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
     Hepatology. 2023;77:1404-1427.
     PubMed     Abstract available
     
     
     
262. TORRES S, Ortiz C, Bachtler N, Gu W, et al
     Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
     Hepatology. 2023;77:1228-1240.
     PubMed     Abstract available
     
     
     March 2023
263. ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
     Quantifying days at home in patients with cirrhosis: a national cohort study.
     Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
     PubMed     Abstract available
     
     
     
264. TRIPATHI D, Reiberger T
     Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
     Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
     PubMed    
     
     
     
265. ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
     Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
     Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
     PubMed     Abstract available
     
     
     
266. HONG T, Xiong X, Chen Y, Wang Q, et al
     Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
     Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
     PubMed     Abstract available
     
     
     
267. ALLAIRE M, Thabut D
     Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
     Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
     PubMed    
     
     
     
268. SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
     Gut microbiome-brain-cirrhosis axis.
     Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
     PubMed     Abstract available
     
     
     February 2023
269. DU K, Maeso-Diaz R, Oh SH, Wang E, et al
     Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
     Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
     PubMed     Abstract available
     
     
     
270. GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
     Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
     Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
     PubMed     Abstract available
     
     
     
271. WU N, Zhou T, Carpino G, Baiocchi L, et al
     Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
     Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
     PubMed     Abstract available
     
     
     
272. ZHANG J, Lyu Z, Li B, You Z, et al
     P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
     Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
     PubMed     Abstract available
     
     
     January 2023
273. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
     Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
     PubMed     Abstract available
     
     
     
274. ALLAIRE M, Thabut D
     Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
     PubMed     Abstract available
     
     
     
275. CHANG D, Truong E, Noureddin M
     Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
     PubMed    
     
     
     
276. SHARPTON SR, Loomba R
     Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
     PubMed     Abstract available
     
     
     
277. TANTAI X, Wang J, Dai S
     Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
     PubMed    
     
     
     
278. MA F, Liu Y, Hu Z, Xue Y, et al
     Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
     PubMed     Abstract available
     
     
     
279. GONG L, Wei F, Gonzalez FJ, Li G, et al
     Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
     PubMed     Abstract available
     
     
     October 2022
280. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
     Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
     Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
     PubMed     Abstract available
     
     
     September 2022
281. KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
     Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
     Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
     PubMed     Abstract available
     
     
     July 2022
282. LIU X, Tan S, Liu H, Jiang J, et al
     Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
     Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum